Funding news
Parabilis Medicines logo

Parabilis Medicines Secures $670

Recently funded · $670.0M UnknownHospitals and Health CareUSView source

Get the full Parabilis Medicines company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Tackling targets long considered undruggable, clinical-stage biopharmaceutical company Parabilis Medicines has raised a substantial $670.0M in new capital. The firm is pioneering a new class of alpha-helical peptides, Helicons, designed to modulate intracellular proteins for serious diseases.

Its lead investigational medicine, zolucatetide, is the first direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is currently being evaluated in clinical trials for various Wnt/β-catenin-driven conditions, including desmoid tumors and familial adenomatous polyposis.

From the source

Joel · Jun 10, 2026

A few weeks ago, I argued that the #biotech industry's next constraint might not be funding. Since then, the market has moved even faster than I expected. In the first half of 2026 alone, biopharma announced $134 billion in M&A, including thirty-three acquisitions worth more than $1 billion.

The IPO window has reopened with roughly $5 billion raised, led by Parabilis Medicines ($670 million), Kailera Therapeutics ($625 million), and Kardigan ($400 million). The momentum hasn't slowed. Last week, Definium Therapeutics raised $805 million to advance multiple simultaneous Phase 3 programs. Ollin Biosciences closed an oversubscribed $330 million Series B ahead of global Phase 3 trials. A

Unlock the full source

CEO quotes, investor details and growth metrics

Start free trial

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Unknown rounds

Companies that recently closed a Unknown round.

#CompanyAmount
1
Clicklease logo

Clicklease

United States

$220.0M
2
Hybar logo

Hybar

United States

$1.1B
3
Wheere logo

Wheere

France

$4.6M
4
Esh-Tech Systems logo

Esh-Tech Systems

Israel

$18.0M
5
Pocket (YC W26) logo

Pocket (YC W26)

United States

$11.0M